Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

1. Periprocedural Outcomes of Direct Oral Anticoagulants vs. Warfarin in Non-Valvular Atrial Fibrillation: A Meta-analysis of Phase III Trials

Periprocedural Outcomes of Direct Oral Anticoagulants vs. Warfarin in Non-Valvular Atrial Fibrillation: A Meta-analysis of Phase III Trials 29794081 2018 10 25 1524-4539 138 14 2018 Oct 02 Circulation Circulation Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. 1402-1411 10.1161/CIRCULATIONAHA.117.031457 Direct oral anticoagulants (DOACs) are surpassing warfarin as the anticoagulant of choice for stroke prevention in nonvalvular (...) atrial fibrillation. DOAC outcomes in elective periprocedural settings have not been well elucidated and remain a source of concern for clinicians. The aim of this meta-analysis was to evaluate the periprocedural safety and efficacy of DOACs versus warfarin in patients with nonvalvular atrial fibrillation. We reviewed the literature for data from phase III randomized controlled trials comparing DOACs with warfarin in the periprocedural period among patients with nonvalvular atrial fibrillation. Substudies from 4

EvidenceUpdates2018

2. Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation

Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Signal - Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Dissemination Centre Discover Portal NIHR DC Discover Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Published on 6 February 2018 In people with atrial fibrillation needing anticoagulant (...) treatment, deaths were fewer in those who had direct acting oral anticoagulants compared with warfarin. The picture is less clear for the risk of stroke and complications such as bleeding in the brain or gut. Apixaban had the best efficacy and safety profile and was cost-effective compared with warfarin. This study pooled the data in all trials reporting efficacy, safety and cost of anticoagulant prevention of stroke events in people with atrial fibrillation. Researchers used a technique called network

NIHR Dissemination Centre2018

3. New generation anticoagulants may be safer than warfarin for people with chronic kidney disease

New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Signal - New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Dissemination Centre Discover Portal NIHR DC Discover New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Published on 26 April 2016 Newer generation anticoagulants appear to reduce the risk of bleeding compared with older anticoagulants like warfarin (...) , when used to prevent clots in people who also have mild to moderate chronic kidney disease. This group of drugs, called direct oral anticoagulants, have been well researched in healthy people with atrial fibrillation or at risk of thromboembolism but this was the first review to look at their safety, in terms of bleeding and risk of bleeding within the brain, in people with kidney disease. As a group, these newer drugs appear safer than older anticoagulants such as warfarin. Evidence from

NIHR Dissemination Centre2018

4. The blood-thinner apixaban is less likely to cause major bleeding than warfarin

The blood-thinner apixaban is less likely to cause major bleeding than warfarin The blood-thinner apixaban is less likely to cause major bleeding than warfarin Dissemination Centre Discover Portal NIHR DC Discover The blood-thinner apixaban is less likely to cause major bleeding than warfarin Published on 16 October 2018 doi: People who take apixaban to prevent blood clots are less likely to suffer major bleeding complications than those taking warfarin. Findings are similar in different groups (...) of people, such as those with irregular heart rhythm (atrial fibrillation) and those who have had joint replacement surgery. Warfarin has long been used as an anticoagulant but needs frequent blood test monitoring. The new class of direct-acting oral anticoagulants does not usually need monitoring and is replacing warfarin. This large NIHR-funded study examined registry data from 196,061 people taking anticoagulants for any reason. Fewer people had intracranial bleeding on the direct acting oral

NIHR Dissemination Centre2018

5. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 30002145 2018 09 28 1528-0020 132 13 2018 Sep 27 Blood Blood Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. 1365-1371 10.1182/blood-2018-04-848333 Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic (...) antiphospholipid syndrome. This is a randomized open-label multicenter noninferiority study with blinded end point adjudication. Rivaroxaban, 20 mg once daily (15 mg once daily based on kidney function) was compared with warfarin (international normalized ratio target 2.5) for the prevention of thromboembolic events, major bleeding, and vascular death in patients with antiphospholipid syndrome. Only high-risk patients triple positive for lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein I

EvidenceUpdates2018

6. New drugs for deep vein thrombosis may offer a safe alternative to warfarin

New drugs for deep vein thrombosis may offer a safe alternative to warfarin Signal - New drugs for deep vein thrombosis may offer a safe alternative to warfarin Dissemination Centre Discover Portal NIHR DC Discover New drugs for deep vein thrombosis may offer a safe alternative to warfarin Published on 20 October 2015 This Cochrane systematic review found that two new types of drugs taken by mouth for deep vein thrombosis were as effective as standard treatment, which most commonly involves (...) treatment by injection followed by warfarin tablets for at least three months. The new drugs have the advantage that they do not require monitoring or dose changes and were associated with a lower risk of bleeding. This high quality review was based on evidence from 11 good quality trials and can be considered reliable. This review did not look at overall cost or cost-effectiveness. NICE has conducted some assessments of individual drugs and is conducting further assessments. Each assessment has

NIHR Dissemination Centre2018

7. Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism

Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism 29974611 2018 09 04 1538-7836 16 9 2018 Sep Journal of thrombosis and haemostasis : JTH J. Thromb. Haemost. Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism. 1775-1778 10.1111/jth.14226 Essentials Factor Xa inhibitors cause more abnormal menstrual bleeding (AUB) than vitamin-K antagonists (VKA). We analyzed data of AUB (...) in women, evaluating dabigatran versus VKA. We observed a 41% lower risk of AUB in women on dabigatran compared to those on VKA. Our findings of lower AUB risk on dabigatran should be corroborated in future studies. Introduction Although direct oral anticoagulants (DOACs) are associated with a better safety profile than warfarin in patients with acute venous thromboembolism (VTE), direct factor Xa inhibitors involve a higher risk of abnormal uterine bleeding (AUB). We aimed to determine the risk of AUB

EvidenceUpdates2018

8. Warfarin

Warfarin Top results for warfarin - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for warfarin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

9. Self-monitoring of warfarin is safe and cost-effective

Self-monitoring of warfarin is safe and cost-effective Signal - Self-monitoring of warfarin is safe and cost-effective Dissemination Centre Discover Portal NIHR DC Discover Self-monitoring of warfarin is safe and cost-effective Published on 21 August 2015 This NIHR-funded systematic review investigated the clinical and cost-effectiveness of self-monitoring by people receiving long-term anticoagulation using vitamin K antagonists, most commonly, warfarin. People receiving warfarin require (...) regular blood tests to see how their blood is clotting and to adjust their dose to avoid bleeding from too high a dose or thrombosis (clots) if the dose drops too low. This is usually done at their GP practice or in hospital clinics. Self-monitoring involves two aspects of care; people self-testing their blood on a machine at home and self-managing, adjusting their warfarin dosage themselves. This review found self-monitoring halved the number of blood clots compared with standard care. Health

NIHR Dissemination Centre2018

10. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.

Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. OBJECTIVE: To investigate the associations between direct oral anticoagulants (DOACs) and risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality compared with warfarin. DESIGN: Prospective open cohort study. SETTING: UK general practices contributing to QResearch or Clinical Practice Research Datalink. PARTICIPANTS: 132 231 warfarin, 7744 (...) dabigatran, 37 863 rivaroxaban, and 18 223 apixaban users without anticoagulant prescriptions for 12 months before study entry, subgrouped into 103 270 patients with atrial fibrillation and 92 791 without atrial fibrillation between 2011 and 2016. MAIN OUTCOME MEASURES: Major bleeding leading to hospital admission or death. Specific sites of bleeding and all cause mortality were also studied. RESULTS: In patients with atrial fibrillation, compared with warfarin, apixaban was associated with a decreased

BMJ2018

11. New generation anticoagulants may be safer than warfarin for people with chronic kidney disease

New generation anticoagulants may be safer than warfarin for people with chronic kidney disease NIHR DC | Signal - New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Published on 26 April 2016 Newer generation anticoagulants appear to reduce the risk of bleeding compared with older (...) anticoagulants like warfarin, when used to prevent clots in people who also have mild to moderate chronic kidney disease. This group of drugs, called direct oral anticoagulants, have been well researched in healthy people with atrial fibrillation or at risk of thromboembolism but this was the first review to look at their safety, in terms of bleeding and risk of bleeding within the brain, in people with kidney disease. As a group, these newer drugs appear safer than older anticoagulants such as warfarin

NIHR Dissemination Centre2018

12. New drugs for deep vein thrombosis may offer a safe alternative to warfarin

New drugs for deep vein thrombosis may offer a safe alternative to warfarin NIHR DC | Signal - New drugs for deep vein thrombosis may offer a safe alternative to warfarin Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal New drugs for deep vein thrombosis may offer a safe alternative to warfarin Published on 20 October 2015 This Cochrane systematic review found that two new types of drugs taken by mouth for deep vein thrombosis were as effective as standard treatment, which most (...) commonly involves treatment by injection followed by warfarin tablets for at least three months. The new drugs have the advantage that they do not require monitoring or dose changes and were associated with a lower risk of bleeding. This high quality review was based on evidence from 11 good quality trials and can be considered reliable. This review did not look at overall cost or cost-effectiveness. NICE has conducted some assessments of individual drugs and is conducting further assessments. Each

NIHR Dissemination Centre2018

13. Self-monitoring of warfarin is safe and cost-effective

Self-monitoring of warfarin is safe and cost-effective NIHR DC | Signal - Self-monitoring of warfarin is safe and cost-effective Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Self-monitoring of warfarin is safe and cost-effective Published on 21 August 2015 This NIHR-funded systematic review investigated the clinical and cost-effectiveness of self-monitoring by people receiving long-term anticoagulation using vitamin K antagonists, most commonly, warfarin. People receiving (...) warfarin require regular blood tests to see how their blood is clotting and to adjust their dose to avoid bleeding from too high a dose or thrombosis (clots) if the dose drops too low. This is usually done at their GP practice or in hospital clinics. Self-monitoring involves two aspects of care; people self-testing their blood on a machine at home and self-managing, adjusting their warfarin dosage themselves. This review found self-monitoring halved the number of blood clots compared with standard care

NIHR Dissemination Centre2018

14. Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation

Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation NIHR DC | Signal - Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Dissemination Centre Discover Portal NIHR DC Discover Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Published on 6 February 2018 In people with atrial fibrillation needing (...) anticoagulant treatment, deaths were fewer in those who had direct acting oral anticoagulants compared with warfarin. The picture is less clear for the risk of stroke and complications such as bleeding in the brain or gut. Apixaban had the best efficacy and safety profile and was cost-effective compared with warfarin. This study pooled the data in all trials reporting efficacy, safety and cost of anticoagulant prevention of stroke events in people with atrial fibrillation. Researchers used a technique

NIHR Dissemination Centre2018

15. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II

Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II 29202209 2017 12 20 2567-689X 117 11 2017 11 Thrombosis and haemostasis Thromb. Haemost. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. 2045-2052 10.1160/TH17-03-0176 Management of acute venous thromboembolism (VTE) with anticoagulants (...) in elderly patients and those with chronic kidney disease poses special challenges. The RE-COVER and RE-COVER II trials showed that dabigatran 150 mg twice daily was as effective as warfarin over 6 months in preventing recurrent VTE, with a lower bleeding risk. We now assess the effects of old age and renal impairment (RI) on pooled trial outcomes in 5,107 patients: 4,504 aged <75 years and 603 aged ≥75 years. The primary efficacy outcome was symptomatic VTE/VTE-related death. Safety outcomes were

EvidenceUpdates2018

16. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation REGULARARTICLE Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial?brillation Surbhi Shah, 1 Faye L. Norby, 2 Yvonne H. Datta, 1 Pamela L. Lutsey, 2 Richard F. MacLehose, 2 Lin Y. Chen, 1 and Alvaro Alonso 3 1 Department of Medicine, Universityof Minnesota Medical School, Minneapolis,MN; 2 Division of Epidemiologyand Community (...) Health, School of Public Health, University of Minnesota, Minneapolis, MN; and 3 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA Key Points ? In AF and cancer pa- tients, rate of bleeding is lower with apixaban, similar in dabigatran and rivaroxaban users, compared to warfarin users. ? Ischemic stroke rates did not differ among anticoagulant users. Incident VTE risk was lower in all DOAC compared with warfarin users

Blood advances2018 Full Text: Link to full Text with Trip Pro

17. Direct oral anticoagulants or warfarin for A fib?

Direct oral anticoagulants or warfarin for A fib? Direct oral anticoagulants or warfarin for A fib? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Direct oral anticoagulants or warfarin for A fib? View/ Open Date 2017-08 Format Metadata Abstract A recent study evaluated the effectiveness of 3 direct oral (...) anticoagulants and warfarin in patients with atrial fibrillation. So which agents came out on top? PRACTICE CHANGER: Use direct oral anticoagulants instead of warfarin in patients with atrial fibrillation because they are just as effective at preventing ischemic stroke and systemic emboli as warfarin, and because apixaban and dabigatran have lower bleeding rates. STRENGTH OF RECOMMENDATION: B: Based on a single, prospective, cohort study. URI Part of Citation Journal of Family Practice, 66(8) 2017: 518-520

PURLS2018

18. Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis

Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis EXCEPTIONALCASEREPORT Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C de?ciency and warfarin-induced skin necrosis Neethu Menon, 1 Ravi Sarode, 2 and Ayesha Zia 1 1 Division of Hematology/Oncology, Department of Pediatrics, and 2 Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX Key Points (...) of a long-term vitamin K antagonist. 1 However, warfarin lowers PC levels (half-life;3 hours) rapidlybeforedecreasingfactorsIIandX(halflife;36-72hours),leadingtotransienthypercoagulability that can cause skin necrosis at treatment outset. 3 Warfarin-induced skin necrosis (WISN) is rare but more likely to occur in severe PC deficiency. 4 Rivaroxaban reversibly inhibits free and bound factor Xa and prevents the thrombin burst during the amplificationphaseofcoagulation.Ithaspredictablepharmacokinetic(PK

Blood advances2018 Full Text: Link to full Text with Trip Pro

19. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II

Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II

EvidenceUpdates2017